Phathom Pharmaceuticals (NAS:PHAT) Volatility

: 72.71% (As of Today)

View and export this data going back to 2019. Start your Free Trial

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2023-03-20), Phathom Pharmaceuticals's Volatility is 72.71%.

Competitive Comparison

For the Biotechnology subindustry, Phathom Pharmaceuticals's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Annual Data Quarterly Data

Phathom Pharmaceuticals Volatility Distribution

For the Biotechnology industry and Healthcare sector, Phathom Pharmaceuticals's Volatility distribution charts can be found below:

* The bar in red indicates where Phathom Pharmaceuticals's Volatility falls in comparison to its industry or sector. The grey bar indicates the Volatility's extreme value range as defined by GuruFocus.

Phathom Pharmaceuticals (NAS:PHAT) Volatility Calculation

The annualized volatility is calculated as following:

σ_A	=	σ_M	*	√12
	=	√ 1/(n-1) ∑(Ri - R')^2	*	√12

Where: σ_M is the monthly volatility, n is the number of months in the period, R_i is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Phathom Pharmaceuticals (NAS:PHAT) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Phathom Pharmaceuticals Volatility Related Terms

Thank you for viewing the detailed overview of Phathom Pharmaceuticals's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.

Phathom Pharmaceuticals (NAS:PHAT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Phathom Pharmaceuticals Inc (NAS:PHAT) » Definitions » Volatility

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, Suite 102, Florham Park, NJ, USA, 07932

Website

https://www.phathompharma.com

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Executives

Frank Karbe	director	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Molly Henderson	officer: CFO and CBO	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Anthony J. Guzzo	officer: VP, Chief Accounting Officer	C/O US SHIPPING PARTNERS L.P., 399 THORNALL STREET, EDISON NJ 08837
Todd P. Branning	officer: Chief Financial Officer	C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Mark Stenhouse	director	5505 ENDEAVOR LANE, MADISON WI 53719
Asit Parikh	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Fhmls Ix, L.l.c.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Azmi Nabulsi	officer: Chief Operating Officer	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
Jonathan S. Edwards	director	C/O PHATHOM PHARMACEUTICALS, INC., 2150 E. LAKE COOK ROAD, SUITE 800, BUFFALO GROVE IL 60089
David A Socks	director, officer: President, CEO, Treas. & Sec.	C/O CADENCE PHARMACEUTICALS, INC., 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130